Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.

Real-life data concerning dupilumab effectiveness and safety in adolescents (≥12 to <18 years) with moderate-to-severe atopic dermatitis (AD) are rarely reported.1 In the adolescent phase III randomized, placebo-controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open label extension (LIBERTY AD PED-OLE)3 dupilumab showed significant signs and symptoms improvement at week-16, with a good safety profile. Herein, we report our real-life experience on AD adolescents treated with dupilumab.